Papillary renal cell carcinoma: Current progress and future directions

Przemyslaw W. Twardowski, Philip Mack, Primo N Lara

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Papillary renal cell carcinoma (pRCC) represents the second most common histologic variant of kidney cancer. It exhibits a different molecular signature than clear-cell carcinoma and is typically not associated with mutations in the VHL (von Hippel-Lindau) tumor suppressor gene. pRCC is less responsive to modern drugs introduced in the management of kidney cancer in the past decade. In this article, the heredity and biology of 2 main variants of pRCC are outlined. New targets that are being explored in the treatment of this disease are discussed, with particular emphasis on inhibition of mesenchymal epithelial transition (MET) and epidermal growth factor receptor (EGFR) pathways. We discuss preclinical data providing rationale for the combination of MET and EGFR inhibitors and review recently completed and ongoing clinical trials that attempt to expand our therapeutic options for this important subset of kidney cancer.

Original languageEnglish (US)
Pages (from-to)74-79
Number of pages6
JournalClinical Genitourinary Cancer
Volume12
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Epithelial-Mesenchymal Transition
Epidermal Growth Factor Receptor
Heredity
Tumor Suppressor Genes
Clinical Trials
Carcinoma
Mutation
Pharmaceutical Preparations
Direction compound
Therapeutics

Keywords

  • ARQ197
  • EGFR pathway
  • Erlotinib
  • MET pathway
  • Tivantinib

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Papillary renal cell carcinoma : Current progress and future directions. / Twardowski, Przemyslaw W.; Mack, Philip; Lara, Primo N.

In: Clinical Genitourinary Cancer, Vol. 12, No. 2, 2014, p. 74-79.

Research output: Contribution to journalArticle

@article{19d453bbdf064a13ad4e469185c9bb7e,
title = "Papillary renal cell carcinoma: Current progress and future directions",
abstract = "Papillary renal cell carcinoma (pRCC) represents the second most common histologic variant of kidney cancer. It exhibits a different molecular signature than clear-cell carcinoma and is typically not associated with mutations in the VHL (von Hippel-Lindau) tumor suppressor gene. pRCC is less responsive to modern drugs introduced in the management of kidney cancer in the past decade. In this article, the heredity and biology of 2 main variants of pRCC are outlined. New targets that are being explored in the treatment of this disease are discussed, with particular emphasis on inhibition of mesenchymal epithelial transition (MET) and epidermal growth factor receptor (EGFR) pathways. We discuss preclinical data providing rationale for the combination of MET and EGFR inhibitors and review recently completed and ongoing clinical trials that attempt to expand our therapeutic options for this important subset of kidney cancer.",
keywords = "ARQ197, EGFR pathway, Erlotinib, MET pathway, Tivantinib",
author = "Twardowski, {Przemyslaw W.} and Philip Mack and Lara, {Primo N}",
year = "2014",
doi = "10.1016/j.clgc.2013.11.013",
language = "English (US)",
volume = "12",
pages = "74--79",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Papillary renal cell carcinoma

T2 - Current progress and future directions

AU - Twardowski, Przemyslaw W.

AU - Mack, Philip

AU - Lara, Primo N

PY - 2014

Y1 - 2014

N2 - Papillary renal cell carcinoma (pRCC) represents the second most common histologic variant of kidney cancer. It exhibits a different molecular signature than clear-cell carcinoma and is typically not associated with mutations in the VHL (von Hippel-Lindau) tumor suppressor gene. pRCC is less responsive to modern drugs introduced in the management of kidney cancer in the past decade. In this article, the heredity and biology of 2 main variants of pRCC are outlined. New targets that are being explored in the treatment of this disease are discussed, with particular emphasis on inhibition of mesenchymal epithelial transition (MET) and epidermal growth factor receptor (EGFR) pathways. We discuss preclinical data providing rationale for the combination of MET and EGFR inhibitors and review recently completed and ongoing clinical trials that attempt to expand our therapeutic options for this important subset of kidney cancer.

AB - Papillary renal cell carcinoma (pRCC) represents the second most common histologic variant of kidney cancer. It exhibits a different molecular signature than clear-cell carcinoma and is typically not associated with mutations in the VHL (von Hippel-Lindau) tumor suppressor gene. pRCC is less responsive to modern drugs introduced in the management of kidney cancer in the past decade. In this article, the heredity and biology of 2 main variants of pRCC are outlined. New targets that are being explored in the treatment of this disease are discussed, with particular emphasis on inhibition of mesenchymal epithelial transition (MET) and epidermal growth factor receptor (EGFR) pathways. We discuss preclinical data providing rationale for the combination of MET and EGFR inhibitors and review recently completed and ongoing clinical trials that attempt to expand our therapeutic options for this important subset of kidney cancer.

KW - ARQ197

KW - EGFR pathway

KW - Erlotinib

KW - MET pathway

KW - Tivantinib

UR - http://www.scopus.com/inward/record.url?scp=84896354741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896354741&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2013.11.013

DO - 10.1016/j.clgc.2013.11.013

M3 - Article

C2 - 24629521

AN - SCOPUS:84896354741

VL - 12

SP - 74

EP - 79

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 2

ER -